

Vaccine and Infectious Disease Organization

2024 Economic Impact Study

PRAXIS
RESEARCH | STRATEGY | RESULTS

Prepared for:
The Vaccine and Infectious Disease Organization
Data prepared by:
Praxis Consulting Inc.

July 2026



The Vaccine and Infectious Disease Organization has evolved into a world-class institute dedicated to the development of vaccines for the protection of human and animal health.

Economic Impact

(2024 Gross Output for Canada)




> \$111M



490 JOBS

(Praxis Consulting)



\$30.4M

in economic activity generated annually by **VIDO staff and trainee alumni** from around the world (2024)

Executive Summary

Since 1975, the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan (USask) has advanced infectious disease research and vaccine development for human and animal health. Today, VIDO is Canada's Centre for Pandemic Research and is home to an international community of scientists, staff and trainees.

VIDO at a glance

 **180+**

staff, students, trainees
and visiting scientists



35+

countries represented
across VIDO's workforce



225+

people on site during
peak periods, including
seasonal research
positions

Specialized research infrastructure includes:

- a new containment level 2 (CL2-Ag) animal housing facility
- a containment level 3 (CL3)-capable biomanufacturing facility
- a CL3 (CL3-Ag) research facility
- future containment level 4 research space under development

About the Study

Praxis Consulting assessed VIDO's economic contribution in three areas:

Operations

The economic activity and employment supported by VIDO in Saskatchewan and across Canada.

Research

The potential economic losses that could be avoided through effective vaccines and outbreak control.

Training and alumni

The economic and workforce contributions of people who have trained or worked at VIDO.



Key Findings

The economic impact of VIDO is significant provincially, nationally, and internationally.

Within Saskatchewan, VIDO generated:

- \$89.2 million in gross output
- \$54.5 million in gross domestic product
- \$22.0 million in labour income
- supported 383 jobs in 2024.

Impacts as a result of potential losses avoided due to vaccine development resulted in:

- \$11.4 billion in total gross output
- \$6.2 billion in gross domestic product
- \$2.5 billion in labour income
- 46,239 jobs supported in 2024

In Canada as a whole, VIDO generated:

- \$111.5 million in gross output
- \$67.2 million in gross domestic product
- \$30.4 million in labour income
- supported 490 jobs in 2024.

Furthermore, VIDO's alumni generate:

- \$2.064 million in gross output for Saskatchewan annually
- \$9.301 million in added gross output for Canada as a whole
- \$7.019 million in gross output internationally

In 2024, VIDO staff generated between approximately \$74,300 and \$92,900 in gross domestic product per employee.



Summary of Results

Provincial Impacts

National Impacts

Impacts of VIDO, including programs and alumni
(2024 figures) are as follows:



384

FTEs relying directly
or indirectly on VIDO



\$89.2M

in total gross output



\$54.5M

in gross domestic
product



\$22M

in labour income



490.3

FTEs relying directly
or indirectly on VIDO



\$111.5

in total gross output



\$67.2M

in gross domestic
product



\$30.4M

in labour income

Impacts of VIDO, as the result of losses avoided through vaccine
development taken as a point-in-time (2024 figures) are as follows:



\$11.4B

in total gross output



\$6.2B

in gross domestic
product



\$2.5B

in labour income



46,239

FTEs directly or
indirectly protected by
vaccine development



\$491.4B

in total gross output



\$266.5B

in gross domestic
product



\$133.5B

in labour income



2,131,822

FTEs directly or
indirectly protected by
vaccine development

Economic Impacts

Potential losses avoided through direct research programs on specific diseases in Canada (2024)

VIDO has several research programs targeting specific diseases. Praxis assessed the impact of bovine TB, African swine fever, animal influenza, RSV-PI3, and broadly protective coronaviruses, summarizing the potential economic benefits of effective vaccines in avoiding outbreak costs. Impacts are presented for the short term, or one year, and do not include longer-term effects such as market restrictions, border closures, or recovery efforts, which can take significantly longer to resolve.

Disease Area	GDP Protected	Jobs Protected	Wages Protected
Bovine Tuberculosis 🐮	\$6.5B	50,000	\$3B
African Swine Fever 🐷	\$5.5B	42,000	\$2.6B
RSV-PI3 🦠	\$6.9B	55,000	\$3.4B
Avian Influenza 🐔	\$425M	3,200	\$200M
Broadly Protective Coronaviruses 🦠	\$247B	2,000,000	\$124B



“What has VIDO meant for your career”?

“...a cornerstone of my career”

“Great education in a reputable research institution.”

“It was one of the greatest and most rewarding research experiences...”

“One of the rare institutions that train and educate students preparing them for industry...”

Results of the alumni survey also revealed that, while VIDO's alumni had considerable international presence, over 40% of respondents remained in Saskatchewan and 80% of alumni have continued work within Canada.

VIDO alumni **earn** at least

 **8.7%**

more than peers with
similar education levels

 **>40%**

VIDO alumni **remained in
Saskatchewan**

 **80%**

VIDO alumni **continued
to work in Canada**



The background of the image features a soft-focus photograph of laboratory glassware. In the foreground, two clear glass vials with white stoppers are visible, partially filled with a light blue liquid. Behind them, a larger, wider glass bottle, also containing the same blue liquid, is slightly out of focus. The overall color palette is dominated by light blues and whites, creating a clean, scientific, and professional atmosphere.

PRA^XIS

RESEARCH | STRATEGY | RESULTS